Allotera Therapeutics closes a $35 million funding round to advance off-the-shelf CAR-T therapies for T-cell cancers, aiming to enhance clinical development and manufacturing.
Amount Raised
$35 Million
Round Type
Funding Round
Saint LouisBiotechnologyHealth CareTherapeuticsInvestors
Description
Allotera Therapeutics has successfully closed a $35 million financing round comprised of equity and venture debt. The funding will support the global pivotal T-RRex clinical trial of their therapy, Sofi-cel, for T-cell cancers. This round brings the total capital raised by Allotera to $150 million. The company's new name reflects its commitment to developing vital therapies for patients with limited treatment options.
Quick answer
Allotera Therapeutics raised $35 Million in a Funding Round round, dated July 8, 2026. Investors: Fidelity Management. Allotera Therapeutics is based in Saint Louis, Missouri, United States.
- How much did Allotera Therapeutics raise?
- Allotera Therapeutics raised $35 Million in a Funding Round round on July 8, 2026.
- Who invested in Allotera Therapeutics?
- Fidelity Management is named as investors in this round.
- What does Allotera Therapeutics do?
- Allotera Therapeutics, Inc. (formerly Wugen, Inc.) is a clinical-stage biotechnology company that specializes in developing allogeneic, off-the-shelf CAR-T cell therapies for hematological malignancies.
- Where is Allotera Therapeutics based and how big is it?
- Allotera Therapeutics is based in Saint Louis, Missouri, United States.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Allotera Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Amylyx Pharmaceuticals raised $500M (Post-IPO Equity) on August 20, 2026.
- Kynexis raised $46M (Series A) on August 19, 2026.
- Abcuro raised $66M (Series D) on August 18, 2026.
- bioAffinity Technologies raised $4M (Post-IPO Equity) on August 14, 2026.
- Apollomics raised $10M on August 14, 2026.
- Khartis Therapeutics raised $50M (Series B) on August 13, 2026.
Who to call at Allotera Therapeutics, and when
A new round usually means Allotera Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Allotera Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Allotera Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Allotera Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Allotera Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Allotera Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.